🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Glioma

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma NCT07538128EARLY Phase 11 site📍 Shanghai Huashan Hospital · Tests: YSCH-01, Atezolizumab (1200 mg every three weeks) LITT for Ultra-early GBM Recurrence NCT07616986NA1 site📍 Bern Insel Gruppe AG, University Hospital Bern · Tests: LITT D2C7-IT + 2141-V11 Combination Post-resection in rGBM NCT06455605Phase 11 site📍 Durham Darell Bigner · Tests: D2C7-IT, 2141 V11 Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial NCT06818331Phase 21 site📍 China The Third Affiliated hospital of Zhejiang Chinese Medical U… · Tests: SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults NCT06305910Phase 11 site📍 Minneapolis OX2 Therapeutics · Tests: Treatment with CD200AR-L Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression NCT06975332NA2 sites📍 Warsaw📍 Warsaw Medical University of Warsaw · Tests: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma NCT07076472EARLY Phase 11 site📍 Rochester Mayo Clinic · Tests: Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography, Electronic Health … A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients NCT06496971Phase 32 sites📍 Taipei📍 Taoyuan NaviFUS Corporation · Tests: Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM NCT05303467Phase 19 sites📍 Birmingham📍 San Diego📍 San Francisco Boston Scientific Corporation · Tests: TheraSphere GBM Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma NCT04547777Phase 11 site📍 Durham Darell Bigner · Tests: D2C7-IT, 2141-V11 Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease NCT07346157Phase 1, Phase 23 sites📍 San Francisco📍 Washington D.C.📍 Seattle Sabine Mueller, MD, PhD · Tests: Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ) Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor NCT05590689Phase 1, Phase 21 site📍 Münster Universität Münster · Tests: Gliolan, Radiodynamic therapy Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas NCT07110246Phase 212 sites📍 Birmingham📍 San Francisco📍 Washington D.C. University of California, San Francisco · Tests: Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma NCT07655869EARLY Phase 12 sites📍 Beijing📍 Beijing Beijing Tiantan Hospital · Tests: [177Lu]Lu-DOTA-EB-RGD2 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 NCT06126744Phase 12 sites📍 New York📍 Durham Duke University · Tests: MVR-C5252 A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma NCT07464925Phase 13 sites📍 Tampa📍 Chicago📍 New York Tetragon Biosciences Ltd · Tests: GLIX1 Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma NCT06410248Phase 11 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma NCT07710690Phase 13 sites📍 Shanghai📍 Wuhan📍 Xi'an Neuregen Therapeutics Co., Ltd. · Tests: NRG-103 A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972Phase 16 sites📍 Beijing📍 Chongqing📍 Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. · Tests: GNC-039 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme NCT00083512n/a1 site📍 Bethesda National Cancer Institute (NCI) A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma NCT06610682EARLY Phase 12 sites📍 Baltimore📍 New York Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Plixorafenib, Retifanlimab 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations NCT05588141Phase 1, Phase 22 sites📍 Jacksonville📍 Bethesda National Cancer Institute (NCI) · Tests: Zotiraciclib Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401Phase 11 site📍 San Francisco Hideho Okada, MD, PhD · Tests: E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical rese… A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma NCT07306299Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Glioma-related multi-target mRNA vaccines Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma NCT06910306NA3 sites📍 Scottsdale📍 New York📍 Columbus Alpha Tau Medical LTD. · Tests: Device :DaRT seeds BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma NCT04903795Phase 11 site📍 Durham Mustafa Khasraw, MBChB, MD, FRCP, FRACP · Tests: hEGFRvIII-CD3 (BRiTE) Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188Phase 1, Phase 21 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… · Tests: LMP744, Conventional Surgery or Biopsy Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma NCT06430424n/a1 site📍 Bordeaux University Hospital, Bordeaux · Tests: Relapsed glioblastoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy